Akers Biosciences Inc  

(Public, LON:AKR)   Watch this stock  
Find more results for John Rauch
+3.75 (1.76%)
Real-time:   3:50PM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 78.75 - 270.00
Open 212.50
Vol / Avg. 0.00/2,135.00
Mkt cap 16.20M*
P/E     -
Div/yield     -
EPS -1.83*
Shares 5.43M
Beta     -
Inst. own 17%
Aug 16, 2016
Q2 2016 Akers Biosciences Inc Earnings Release (Estimated) Add to calendar
Jun 24, 2016
Akers Biosciences Inc Annual Shareholders Meeting (Estimated)
May 12, 2016
Q1 2016 Akers Biosciences Inc Earnings Call - Webcast
May 12, 2016
Q1 2016 Akers Biosciences Inc Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -204.46% -440.27%
Operating margin -205.54% -457.78%
EBITD margin - -421.54%
Return on average assets -81.10% -74.73%
Return on average equity -103.33% -86.99%
Employees 36 -
CDP Score - -


201 Grove Rd
WEST DEPTFORD, NJ 08086-2231
United States - Map
+1-856-8488698 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Officers and directors

Thomas James Knox Chairman of the Board
Age: 74
John J. Gormally Chief Executive Officer
Raymond Francis Akers Jr. Ph.D. Co-Founder, Chief Scientific Director, Director
Age: 57
John C. Cheneval Executive Vice President, Sales and Marketing
Gary M. Rauch Senior Vice President - Finance, Treasurer
Age: 59
Christopher Ellis Vice President - Global Marketing
Robert E. Andrews Non-Executive Director
Age: 53
Raza Bokhari Non-Executive Director
Age: 48
Brandon Thomas Knox Independent Director
Age: 35
Gavin Edwin David Moran Independent Director
Age: 43